Las Condes 26 03

106 / 164

366
[REV. MED. CLIN. CONDES - 2015; 26(3) 357-366]
Clinical features and diagnosis. Accedido el 30
de Diciembre de 2014.
22. Quirce S, Contreras G, Dybuncio A, Chan-Yeung M. Peak expiratory
flow monitoring is not a reliable method for establishing the
diagnosis of occupational asthma. Am J Respir Crit Care Med 1995;
152 (3): 1100-2.
23. Oasys and occupational asthma. Disponible en http://www.
24. Hytönen M, Kanerva L, Malmberg H, et al. The risk of occupational
rhinitis. Int Arch Occup Environ Health 1997; 69: 487-90.
25. Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the
lung in the 21st century: an update. Clin Respir J 2014; 8: 1–10.
26. Stayner L, Welch LS, Lemen R. The Worldwide Pandemic of Asbestos-
Related Diseases. Annu Rev Public Health 2013; 34: 205-16.
27. Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced
lung disease. Annu Rev Pathol. 2013 Jan 24; 8: 161-87.
28. Greillier L. Astoul P. Mesothelioma and Asbestos-Related Pleural
Diseases Respiration 2008; 76: 1–15.
29. Vicencio M, Oyonarte M. Enfermedades Pleurales; en Enfermedades
respiratorias. 2° Edición. Mediterráneo, 2011. p 939 – 77.
30. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N et al. Asbestos
exposure, pleural mesothelioma, and serum osteopontin levels. N
Engl J Med. 2005; 353 (15):1564-73.
31. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington
J et al. Fibulin-3 as a blood and effusion biomarker for pleural
mesothelioma. N Engl J Med. 2012; 367 (15): 1417-27.
32. Rodríguez JA, Rodríguez E, Rodríguez D, Alfageme I, Quero A, Roza
D et al. Serum levels of soluble mesothelin-related peptides in
malignant and nonmalignant asbestos-related pleural disease:
relation with past asbestos exposure. Cancer Epidemiol Biomarkers
Prev. 2009; 18 (2): 646-50.
33. J. Remona, N. Reguartb, J. Corralc, P. Lianesa. Malignant pleural
mesothelioma: New hope in the horizon with novel therapeutic
strategies. Cancer Treat Rev 2015; 41 (1): 27–34.
34. International Labour Office. D132. Committee on Safety and
Health International Labour Office, Conference 95, 2006. Geneva
35. Ministerio de Salud. Prohíbe Uso del Asbesto en productos que
indica. Decreto 656, publicado 13-01- 2001. Chile
36. Swapnil J. Paralikar and Jagdish H. Paralikar. High-altitude
medicine. Indian J Occup Environ Med. 2010; 14 (1): 6–12.
37. Farías JG, Jiménez D, Osorio J, Zepeda AB, Figueroa CF, Pulgar VM.
Acclimatization to chronic intermittent hypoxia in mine workers:
a challenge to mountain medicine in Chile. Biol Res 2013; 46:
59-67.
38. West J. Fisiología Pulmonar. 7a Edicion. Edit Panamericana.
39. Basnyat B, Murdoch DR. High-altitude illness .Lancet 2003; 361:
1967–74.
40. Hackett PH, Roach PR. High altitude illness. N Engl J Med 2001;
345 (2): 107-14.
41. Undurraga F, Undurraga A. Edema pulmonar de gran altura. Rev
Chil Enf Respir 2003; 19: 113 – 16.
42. Raitt S. High altitude cerebral oedema during adventure training
on Munt Kenya. J R Army Corps 2012; 158 (3): 245 – 7.
43. Richalet JP, Rivera M, Maignan M, Pham I, Privat C, León-Velarde F.
Pulmonary Hypertension and Monge’s Disease. PVRI Review 2009;
1 (2): 114-19.
44. Low EV, Avery AJ, Gupta V, Schedlbauer A, Grocott MP. Identifying
the lowest effective dose of acetazolamide for the prophylaxis of
acute mountain sickness: systematic review and meta-analysis.
BMJ 2012; 345: e6779.
45. Barash IA, Beatty C, Powell FL, Prisk GK, West JB. Nocturnal oxygen
enrichment of room air at 3800 meter altitude improves sleep
architecture. High Alt Med Biol. 2001 ;2 (4) :525-33.
46. Salinas M, Contreras G, Vera A. Administración personalizada
de oxígeno para trabajo en altitud. VIII World Congress on High
Altitude Medicine and Physiology. 2010.